drugset / Trial / NCT07120971

Metformin for Premature Infants With Bronchopulmonary Dysplasia

NCT07120971

Phase 0 Recruiting 40 enrolled Medical College of Wisconsin
Non-randomizedSequentialOpen-labelBasic science

Summary

The overall objective of this study is to investigate the role of metformin in decreasing lung injury and promoting lung growth in premature infants. There are two phases to this pilot study. For Phase 0, the goal is to investigate the safety and tolerance of oral metformin in premature who have been diagnosed with bronchopulmonary dysplasia (BPD) at 36-44 weeks gestation. For Phase 1, the goal is to investigate metformin safety and tolerance in extremely premature infants who are 7-30 days old who have an increased risk of BPD. The main questions it aims to answer are: * how well do older premature infants tolerate metformin? * how well do younger premature infants tolerate metformin?

Timeline

Start
2025-12-19
Primary completion
2028-09-01
Completion
2030-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 5 mg/kg Oral
Subject Metformin Small molecule 10 mg/kg Oral
Subject Metformin Small molecule 15 mg/kg Oral
Subject Metformin Small molecule 20 mg/kg Oral
Subject Metformin Small molecule 25 mg/kg Oral